Loading…
Loading…
The Columbia Seligman Premium Technology Growth Fund is a closed-end equity mutual fund, overseen by Columbia Management Investment Advisers, LLC. This U.S.-domiciled fund, established on November 30, 2009, (and formerly known as the Seligman Premium Technology Growth Fund, Inc.) allocates capital to public equity markets. Its core investment strategy involves primarily targeting growth companies within the technology sector. The fund's portfolio is built through fundamental analysis, identifying businesses that exhibit strong growth prospects, attractive valuations, and the capacity to…
Is STK's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
The Columbia Seligman Premium Technology Growth Fund (STK) offers strong total returns, outperforming comparable ETFs like TDVI, and currently trades at a 6.57% discount to NAV. STK's active management and AI hardware exposure drive outperformance, but increase risk in tech downturns; TDVI provides more conservative, income-focused exposure with monthly distributions. STK's dynamic option strategy and capital gains support variable payouts, while TDVI's index-limited holdings restrict upside but offer steadier income for lifestyle investors.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presentations of data for STK-002 at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 represents a novel approach to Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder, by targeting.
BOSTON--(BUSINESS WIRE)--Today, Columbia Seligman Premium Technology Growth Fund, Inc. (NYSE: STK) (the Fund) declared a fourth-quarter distribution, pursuant to its managed distribution policy, in the amount of $0.4625 per share, which is equal to a quarterly rate of 2.3125% (9.25% annualized) of the $20.00 offering price in the Fund's initial public offering in November 2009. The fourth-quarter distribution of $0.4625 per share is equal to a quarterly rate of 0.8601% (3.44% annualized) of the.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presentations of data for STK-002 at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 is an investigational medicine designed to target the underlying cause of Autosomal Dominant Optic Atrophy (ADOA) by increasing OPA1.
Not everyone wants to or needs to retire early. After all, a 9-5 day job brings steady income, a sense of purpose and discipline, and keeps one engaged in physical and mental activity. Still, one size does not fit all. There would be many folks who like the idea of retiring from a 9-5 job in their 40s or early 50s and pursuing something they have always dreamt about. We will discuss what it really takes to retire early and how to go about investing for early retirement, also known as FIRE (Financially Independent Retire Early).